Skip to content
    WVE
    Earnings call· Jun 2026(Q2 FY26)

    Wave Life Sciences Q2 FY26 earnings call WVE

    Jul 30, 2026 Source

    Executive summary

    Wave Life Sciences Q2 FY26 — Obesity and AATD Programs Advance, Regulatory Pathway for 006 Explored

    Wave Life Sciences advanced its lead RNAi and RNA editing programs, WVE-007 for obesity and WVE-006 for AATD, into their next development stages, leveraging proprietary chemistry and human genetic insights. The company is actively pursuing an accelerated approval pathway for WVE-006 and initiating combination and maintenance studies for WVE-007, while maintaining a strong cash position. The strategy includes exploring partnerships for DMD programs amidst a changing landscape.

    Highlights

    5

    • WVE-007 for obesity showed robust and durable silencing, supporting once or twice yearly dosing, with substantial reductions in visceral and subcutaneous fat without muscle loss.

    • WVE-006 for AATD demonstrated a compelling therapeutic profile, restoring dynamic AAT protein response and addressing both lung and liver manifestations.

    • FDA granted a meeting request to discuss an accelerated approval pathway for WVE-006, expected at the end of summer.

    • Ended the quarter with $490.6 million in cash, cash equivalents, and marketable securities, sufficient to fund operations into Q3 2028.

    • WVE-007 Phase IIa dosing is underway in individuals with higher BMI and comorbidities, with strong enrollment interest.

    Concerns

    5

    • Revenue for Q2 FY26 was $2.3 million, down from $8.7 million in Q2 FY25.

    • R&D expenses increased to $51.3 million in Q2 FY26 from $43.5 million in Q2 FY25 due to clinical program advancement.

    • G&A expenses increased to $24.8 million in Q2 FY26 from $18 million in Q2 FY25 to support expanding pipeline.

    • Net loss widened to $69.4 million in Q2 FY26 from $50.5 million in Q2 FY25.

    • DMD programs (N531, 003) are exploring partnership opportunities due to evolving regulatory and commercial landscape, with potential NDA filing contingent on partnership.

    Guidance & targets

    7
    CategoryTargetConfidence
    WVE-007 combination and maintenance studies initiation
    Initiate clinical studies
    medium materiality
    High
    WVE-008 CTA submission
    CTA submission
    medium materiality
    High
    Cash runway
    Into Q3 2028
    high materiality
    High
    Annual Investor Day
    Host event
    low materiality
    High
    WVE-007 Phase I 600mg cohort data
    Share additional data
    medium materiality
    High
    WVE-006 600mg monthly dosing cohort data
    Share data
    medium materiality
    High
    WVE-006 FDA meeting for accelerated approval
    Meeting with FDA
    high materiality
    High

    Operational metrics

    20
    Revenue
    $2.3Mdown from $8.7M in Q2 FY25
    Q2 FY26

    Relates to ongoing collaboration agreement with GSK.

    R&D expenses
    $51.3Mup from $43.5M in Q2 FY25
    Q2 FY26

    Primarily reflects continued investment in advancing clinical programs, including preparation for Phase IIa INLIGHT and RNA editing pipeline progress.

    SG&A expenses
    $24.8Mup from $18M in Q2 FY25
    Q2 FY26

    Primarily reflects costs associated with supporting expanding pipeline and preparing for next stages of development.

    Net loss
    $69.4Mwidened from $50.5M in Q2 FY25
    Q2 FY26

    Result of increased R&D and G&A expenses.

    Cash & investments balance
    $490.6Mnot stated
    Q2 FY26 end

    Sufficient to fund operations into Q3 2028.

    Addressable market
    175 millionnot stated
    current

    Individuals living with obesity.

    Addressable market
    1 billionnot stated
    current

    Individuals living with obesity.

    Visceral fat reduction
    5% to 10%not stated
    not stated

    Reduction in visceral fat mass associated with positive health outcomes.

    Visceral fat-to-muscle ratio (VMR) improvement
    16.5%single dose
    Phase I

    Observed with a single dose of 007 in Phase I population.

    Visceral fat-to-muscle ratio (VMR) improvement
    12.2%weekly semaglutide
    Phase II BELIEVE study

    Achieved with weekly semaglutide in the Phase II BELIEVE study.

    Visceral fat-to-muscle ratio (VMR) improvement
    18.8%not stated
    not stated

    Observed with bimagrumab.

    GLP-1 therapy discontinuation rate
    up to 70%not stated
    within first year of treatment

    Many patients discontinue due to tolerability, treatment burden, or anhedonia.

    Addressable market
    200,000not stated
    current

    Individuals living with homozygous PiZZ-AATD.

    Addressable market
    9 millionnot stated
    current

    Homozygous PNPLA3 I148M carriers.

    Liver disease mortality risk
    ninefold highervs noncarriers
    not stated

    Homozygous PNPLA3 I148M individuals have a ninefold higher risk of dying from liver disease.

    PNPLA3 editing threshold
    50%not stated
    not stated

    Threshold expected to lower risk for liver disease, based on human genetics observations where risk reduction from homozygous to heterozygous state is more than 80%.

    PNPLA3 liver disease risk reduction
    more than 80%homozygous to heterozygous state
    not stated

    Risk reduction observed in human genetics studies.

    Waist circumference reduction
    3.3%not stated
    Phase I

    Observed in Phase I otherwise healthy patients with WVE-007.

    Liver fat reduction (benchmark)
    44%not stated
    not stated

    Achieved by other therapies in high BMI, high fat settings, greater than existing approved MASH therapies.

    Visceral fat reduction
    14-15%not stated
    Phase I

    Observed in Phase I otherwise healthy patients with WVE-007.

    Deals & partnerships

    2
    GSKOngoing collaboration agreement

    Revenue for Q2 FY26 was $2.3 million compared to $8.7 million in Q2 FY25.

    Not stated (potential partners)Seek partnership opportunities for HD and DMD programs

    Given evolving regulatory and commercial landscape in DMD, exploring potential partnerships in advance of filing an NDA for N531.

    Risks & headwinds

    3
    High discontinuation rates for GLP-1 therapiesWithin the first year of treatment

    Up to 70% of patients discontinue within the first year.

    Mitigation: WVE-007 maintenance therapy could address tolerability, treatment burden, or anhedonia issues.

    Evolving regulatory and commercial landscape in DMDOngoing

    Not quantified.

    Mitigation: Exploring potential partnerships for N531 and 003 in advance of filing an NDA for N531. Evaluating the pathway for existing PMO 53 Golodirsen's potential full approval.

    Silencing approaches for PNPLA3 liver disease may exacerbate the disease

    Dose-dependent increases in liver enzymes observed in clinical trials of PNPLA3 silencing.

    Mitigation: WVE-008 uses an RNA editing approach to restore functional protein, which is expected to reverse steatosis and fibrosis, rather than silencing.

    What to watch in Q3 FY26

    5

    WVE-006 accelerated approval pathway discussion with FDA

    End of summer (2026)
    CurrentFDA granted meeting request
    TargetFeedback from FDA on potential accelerated approval pathway and registrational study design

    Why it matters

    This will inform the development timeline and potential market entry for WVE-006, a key RNA editing program for AATD.

    We're excited to announce today that the FDA granted our request for a meeting, which is planned for the end of this summer. During this, we intend to discuss a potential accelerated approval pathway for 006 in AATD.

    Q&A highlights

    6

    Confirm if Phase IIa aims for 5% weight loss for obesity indication and how 007 combination therapy differentiates from others.

    Paul Bolno confirmed the Phase IIa is designed to elicit the regulatory threshold of 5% weight loss, but also to unlock broader cardiometabolic indications (MASH, T2D) by evaluating biomarkers like MRI-PDFF, HbA1c, and lipids. For combination therapy, he expects 007 to show better data due to greater potency and durability, and highlighted maintenance as a unique differentiation opportunity.

    “the Phase IIa is designed, as you point out, to be able to elicit that regulatory and cross that regulatory threshold of 5%.”

    asked by Yun Zhong · answered by Paul Bolno

    2 min read6 chapters

    Detailed Narrative

    01

    Proprietary Chemistry and Platform Advancements

    Wave Life Sciences emphasizes its proprietary chemistry and SpiNA sRNA design as key differentiators, enhancing potency and durability compared to industry-leading sRNA designs. This platform enables rapid advancement from novel genetic targets to clinical proof of mechanism, as demonstrated by recent positive data sets. The company plans to host an Annual Investor Day in the fall to highlight further platform advancements and work on its bifunctional modality.

    02

    WVE-007 for Obesity and Cardiometabolic Diseases

    WVE-007, an INHBE GalNAc-siRNA, aims to address obesity by selectively reducing excess fat (visceral and subcutaneous) while preserving skeletal muscle, a differentiated approach from incretin therapies. The Phase IIa INLIGHT trial is enrolling individuals with higher BMIs (35-50) and comorbidities, with and without type 2 diabetes, across two dose levels (240mg and 400mg) in four cohorts of 40 patients each. This design allows for evaluation of body composition, weight loss, and potential in MASH, type 2 diabetes, and other cardiometabolic diseases.

    03

    WVE-007 Combination and Maintenance Strategies

    Preclinical data supports combination with incretins, showing approximately twofold greater weight loss, and post-incretin maintenance, demonstrating the ability to curtail weight regain. These strategies aim to address high GLP-1 discontinuation rates (up to 70% within the first year) due to tolerability, treatment burden, or anhedonia, offering a new commercial frontier for sustained health benefits. Clinical studies for both combination and maintenance are planned to initiate this year.

    04

    WVE-006 for Alpha-1 Antitrypsin Deficiency (AATD)

    WVE-006 is an RNA editing candidate designed to treat both lung and liver manifestations of AATD by restoring dynamic AAT protein response. The goal is to recapitulate an MZ-like phenotype, reducing Z-AAT and providing protective basal M-AAT levels with a preserved acute phase response. The FDA has granted a meeting request for the end of summer to discuss a potential accelerated approval pathway for 006, which could inform registrational plans for the 200,000 individuals in the U.S. and Europe living with homozygous ZZ AATD.

    05

    WVE-008 for PNPLA3 Liver Disease

    WVE-008 is the second RNA editing candidate, targeting homozygous PNPLA3 I148M liver disease, affecting 9 million individuals in the U.S. and Europe who have a ninefold higher risk of dying from liver disease. The RNA editing approach aims to correct the I148M variant to restore functional PNPLA3 activity and lipid mobilization, reversing steatosis and fibrosis, contrasting with silencing approaches that may exacerbate the disease. A CTA submission is on track for 2026, with plans to leverage genotyped populations for efficient enrollment.

    06

    DMD Program Strategy

    Wave Life Sciences is exploring potential partnerships for its Duchenne Muscular Dystrophy (DMD) programs, N531 and 003, in advance of filing an NDA for N531. This decision is influenced by the evolving regulatory and commercial landscape in DMD, including the potential full approval of existing therapies, and aims to ensure prudent investment of funds.

    AI-generated summary of the company’s earnings call. Not investment advice.